新辅助治疗在可手术乳腺癌中的应用

目的观察新辅助化疗对可手术乳腺癌患者的临床应用价值。方法选取我院经空芯针活检组织学诊断证实110例可手术的乳腺癌患者,随机给予TThp方案（多西他赛、吡柔比星）或TE方案（多西他赛、表柔比星）新辅助化疗2～4个周期,化疗两周后手术,评价其近期疗效、毒性反应及对术式选择的影响。结果全组患者原发灶的总有效率为87.2%,可保乳率由12.7%提高到41.8%（P〈0.05）,手术切除率达到97.2%。常见不良反应：白细胞减少、恶心呕吐、脱发等。结论新辅助化疗明显提高了可手术乳腺癌患者的保乳机率,降低了临床分期,缩小了手术范围,提高了患者的术后生存质量。

Application of neoadjuvant chemotherapy for operable breast cancer

Objective To investigate the clinical value of neoadjuvant chemotherapy in the treatment of operable breast cancer. Methods A total of 120 patients with pathologically proven operable breast cancer were randomized into two groups to receive 2-4 cycles of neoadjuvant chemotherapy with docetaxel combined with pirarubicin (TThp) or docetaxel combined with epirubicin (TE). Operations were performed two weeks after the neoadjuvant chemotherapy. The short-term therapeutic effect, toxic reaction and the impact of ...